Cat. No.: HY-78263

MNS

(Synonyms: NSC 170724; 5-(2-Nitrovinyl)benzodioxole)

3 Cited Publications

Avis client

Based on 3 publication(s) in Google Scholar

MNS (NSC 170724), the beta-nitrostyrene derivative, is an orally active tyrosine kinase inhibitor, a broad-spectrum antiplatelet agent, and a PANoptosis inhibitor. MNS inhibits Src, Syk, and FAK with IC₅₀ of 27.3, 2.8, and 97.6 μM, respectively. MNS inhibits NLRP3 inflammasome and β1 integrin. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC₅₀ values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS is cytotoxic to a variety of cells.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 1485-00-3
Formule: C₉H₇NO₄
Masse moléculaire:193.16

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

MNS Chemical Structure

CAS No.: 1485-00-3

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]

NLRP3 inflammasome

Voir tous les produits spécifiques à Isoform Src :

Voir tous les produits spécifiques à Isoform NOD-like Receptor (NLR) :

Voir tous les produits spécifiques à Isoform Integrin :

Cellular Effect

Cell Line	Type	Value	Description	References
BXPC-3	GI₅₀	1.7 μg/mL Compound: 4m	Cytotoxicity against human BxPC3 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human BxPC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
DU-145	GI₅₀	1.8 μg/mL Compound: 4m	Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
HBL-100	IC₅₀	>20 μM Compound: MNS	Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay	[PMID: 20850977]
HeLa	IC₅₀	3.9 μM Compound: 2	Inhibition of proteasomal turnover of p97-independent ODD-luciferase reporter substrate in human HeLa cells incubated for 120 mins by luciferase reporter gene assay Inhibition of proteasomal turnover of p97-independent ODD-luciferase reporter substrate in human HeLa cells incubated for 120 mins by luciferase reporter gene assay	[PMID: 33476933]
KM-20L2	GI₅₀	1.8 μg/mL Compound: 4m	Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
L02	IC₅₀	39.24 μM Compound: MNS	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35428012]
L02	IC₅₀	41.1 μM Compound: MNS	Cytotoxicity against human L-02 cells incubated for 24 hrs by MTT assay Cytotoxicity against human L-02 cells incubated for 24 hrs by MTT assay	[PMID: 34506712]
MCF7	GI₅₀	0.58 μg/mL Compound: 4m	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
MDA-MB-231	IC₅₀	14 μM Compound: MNS	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 20850977]
NCI-H460	GI₅₀	2 μg/mL Compound: 4m	Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
P388	ED₅₀	2 μg/mL Compound: 4m	Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]
Platelet	IC₅₀	14 μM Compound: MNS	Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins before thrombin challenge by turbidimetry analysis Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation preincubated for 3 mins before thrombin challenge by turbidimetry analysis	[PMID: 20850977]
Platelet	IC₅₀	7.2 μM Compound: MNS	Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation preincubated for 3 mins before collagen challenge by turbidimetry analysis Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation preincubated for 3 mins before collagen challenge by turbidimetry analysis	[PMID: 20850977]
SF-268	GI₅₀	1.9 μg/mL Compound: 4m	Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 19709889]

In Vitro

MNS (48 h) shows cytotoxicity against human BxPC3, DU145, and KM20L2 cells, with GI₅₀ of 1.7 μg/mL, 1.8 μg/mL, 1.8 μg/mL, respectively^[3].
MNS (1-20 μM, 1-15 h) inhibits adhesion and migration of MDA-MB-231 cells by suppressing β1 integrin function and surface protein disulfide isomerase^[4].
MNS (1-10 μM, 15 min) inhibits NLRP3 inflammasome activation in LPS-primed BMDMs by blocking assembly of the inflammasome^[5].
MNS (2.5-10 μM, 4-24 h) decreases the motility and colony formation of osteosarcoma cells^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[4]

Cell Line:

MDA-MB-231
Concentration:

1, 2, 5, 10, 20 μM
Incubation Time:

15 h
Result:

Concentration-dependently prevented MDA-MB-231 cells from migrating.
Failed to migrate into and close a wound at 10 and 20 μM.
Abolished the migration at 5 μM.

In Vivo

MNS (20 mg/kg, i.p.) ameliorates experimental burn wound progression in Wistar rats by inhibiting the NLRP3 inflammasome activation^[7].
MNS (30 mg/kg, p.o., 5 days) alleviates DSS-induced mouse colitis by inhibiting the NLRP3 inflammasome^[8].
MNS (20 mg/kg, i.p., 30 min before reperfusion) significantly protects the kidneys from RIR injury in rats by reducing PANoptosis through specific inhibition of NLRP3^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1485-00-3
Appearance Solid
Masse moléculaire 193.16
Formule C₉H₇NO₄
Color Light yellow to green yellow
SMILES

O=[N+]([O-])/C=C/C1=CC(OCO2)=C2C=C1
Synonyms

NSC 170724; 5-(2-Nitrovinyl)benzodioxole
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All

Sort by:

Journal Impact Factor

Cell Res

Signal-induced NLRP3 phase separation initiates inflammasome activation. [Abstract]

2025 Apr 1. PMID: 40164768
Cell Chem Biol

Pantothenate kinase is an effective target for antifungal therapy. [Abstract]

2025 May 15;32(5):710-721.e6. PMID: 40378822
Res Sq

2025 Jul 17.

Solvant et solubilité

In Vitro:

DMSO : 50 mg/mL (258.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.1771 mL

25.8853 mL

51.7706 mL

5 mM

1.0354 mL

5.1771 mL

10.3541 mL

10 mM

0.5177 mL

2.5885 mL

5.1771 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (12.94 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (12.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (280 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Wang WY, et al. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007;74(4):601-611. [Content Brief]

[2]. Wang WY, et al. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor. Mol Pharmacol. 2006;70(4):1380-1389. [Content Brief]

[3]. Pettit RK, et al. E-Combretastatin and E-resveratrol structural modifications: antimicrobial and cancer cell growth inhibitory beta-E-nitrostyrenes. Bioorg Med Chem. 2009 Sep 15;17(18):6606-12. [Content Brief]

[4]. Chen IH, et al. 3,4-Methylenedioxy-β-nitrostyrene inhibits adhesion and migration of human triple-negative breast cancer cells by suppressing β1 integrin function and surface protein disulfide isomerase. Biochimie. 2015 Mar;110:81-92. [Content Brief]

[5]. He Y, et al. 3,4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2014 Jan 10;289(2):1142-50. [Content Brief]

[6]. Messerschmitt PJ, et al. Osteosarcoma Phenotype Is Inhibited by 3,4-Methylenedioxy-β-nitrostyrene. Sarcoma. 2012;2012:479712. [Content Brief]

[7]. Xiao M, et al. 3,4-Methylenedioxy-β-Nitrostyrene Ameliorates Experimental Burn Wound Progression by Inhibiting the NLRP3 Inflammasome Activation. Plast Reconstr Surg. 2016 Mar;137(3):566e-575e. [Content Brief]

[8]. Zheng J, et al. 3,4-Methylenedioxy-β-Nitrostyrene Alleviates Dextran Sulfate Sodium-Induced Mouse Colitis by Inhibiting the NLRP3 Inflammasome. Front Pharmacol. 2022 Jun 15;13:866228. [Content Brief]

[9]. Uysal E, et al. Targeting the PANoptosome with 3,4-Methylenedioxy-β-Nitrostyrene, Reduces PANoptosis and Protects the Kidney against Renal İschemia-Reperfusion Injury. J Invest Surg. 2022 Nov-Dec;35(11-12):1824-1835. [Content Brief]

[10]. Wang L, et al. Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases. Cell Death Dis. 2023 Dec 21;14(12):851. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.1771 mL	25.8853 mL	51.7706 mL	129.4264 mL
	5 mM	1.0354 mL	5.1771 mL	10.3541 mL	25.8853 mL
	10 mM	0.5177 mL	2.5885 mL	5.1771 mL	12.9426 mL
	15 mM	0.3451 mL	1.7257 mL	3.4514 mL	8.6284 mL
	20 mM	0.2589 mL	1.2943 mL	2.5885 mL	6.4713 mL
	25 mM	0.2071 mL	1.0354 mL	2.0708 mL	5.1771 mL
	30 mM	0.1726 mL	0.8628 mL	1.7257 mL	4.3142 mL
	40 mM	0.1294 mL	0.6471 mL	1.2943 mL	3.2357 mL
	50 mM	0.1035 mL	0.5177 mL	1.0354 mL	2.5885 mL
	60 mM	0.0863 mL	0.4314 mL	0.8628 mL	2.1571 mL
	80 mM	0.0647 mL	0.3236 mL	0.6471 mL	1.6178 mL
	100 mM	0.0518 mL	0.2589 mL	0.5177 mL	1.2943 mL

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

MNS

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Antioxidant Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Anti-Pancreatic Cancer Compound Library

Angiogenesis-Related Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Coagulation and Anti-coagulation Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Extracellular Vesicles (EVs) Compound Library

Inflammasomes related Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Pattern Recognition Receptors Library

Publications Citing Use of MedChemExpress (MCE) MNS

Voir tous les produits spécifiques à Isoform Src

Voir tous les produits spécifiques à Isoform NOD-like Receptor (NLR)

Voir tous les produits spécifiques à Isoform Integrin

Activité biologique

Chemical Information

Publications (3)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

MNS Related Classifications

HY-78263 Related Classifications